119 related articles for article (PubMed ID: 9713491)
1. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.
Kiura K; Watarai S; Ueoka H; Tabata M; Gemba K; Aoe K; Yamane H; Yasuda T; Harada M
Anticancer Res; 1998; 18(4C):2957-60. PubMed ID: 9713491
[TBL] [Abstract][Full Text] [Related]
2. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.
Kiura K; Watarai S; Shibayama T; Ohnoshi T; Kimura I; Yasuda T
Anticancer Drug Des; 1993 Dec; 8(6):417-28. PubMed ID: 8286010
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
Gu T; Ohashi R; Cui R; Tajima K; Yoshioka M; Iwakami S; Sasaki S; Shinohara A; Matsukawa T; Kobayashi J; Inaba Y; Takahashi K
Lung Cancer; 2009 Nov; 66(2):176-83. PubMed ID: 19285749
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
8. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells.
Noguchi M; Kabayama K; Uemura S; Kang BW; Saito M; Igarashi Y; Inokuchi J
Glycobiology; 2006 Jul; 16(7):641-50. PubMed ID: 16571667
[TBL] [Abstract][Full Text] [Related]
9. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of a cisplatin-induced human hepatocellular carcinoma drug-resistant cell line and its biological characteristics].
Yang JX; Tang WX
Ai Zheng; 2002 Aug; 21(8):872-6. PubMed ID: 12478896
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
Kimura I; Ohnoshi T; Hiraki S; Miyamoto H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
14. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody.
Fukumoto H; Nishio K; Ohta S; Hanai N; Saijo N
Int J Cancer; 1996 Sep; 67(5):676-80. PubMed ID: 8782657
[TBL] [Abstract][Full Text] [Related]
15. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis.
Yoshida S; Fukumoto S; Kawaguchi H; Sato S; Ueda R; Furukawa K
Cancer Res; 2001 May; 61(10):4244-52. PubMed ID: 11358851
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
[TBL] [Abstract][Full Text] [Related]
18. Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity.
Hanibuchi M; Nishioka Y; Yanagawa H; Yano S; Parajuli P; Bando M; Sone S
Oncol Res; 2000; 12(4):173-9. PubMed ID: 11341466
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
20. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line.
Yang JX; Luo Y; Qiu HM; Tang WX
Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
